Table 3. Survival Estimates.

Recurrence-Free Survival Estimates
	N at risk	N Events	5-Year Estimate	95% Confidence Interval	P-Value
All		33	57.8 %	(47.3%, 0.6 %)
Race
Black	18	10	38.7 %	(20.4, 73.3%)
Hispanic	8	2	75.0 %	(50.3%, 100%)
White	50	20	63.6 %	(51.5, 78.6%)
Other	1	1	--	--	0.237
Age
≤ 50	36	13	65.3%	(50.2%, 85.0%)
> 50	41	20	51.2%	(38.0%, 69.1%)	0.121
Menopausal Status
Pre-menopausal	29	12	62.8%	(46.5%, 84.7%)
Post-menopausal	48	21	54.6%	(41.7%, 71.5%)	0.553
Histology
Ductal	64	28	57.7%	(46.4%, 71.8%)
Other	13	5	59.8%	(37.8%, 94.7%)	0.951
Pathological Stage
I and II	47	13	74.1%	(61.7%, 89.0%)
III	30	20	32.3%	(19.1%, 54.7%)	<0.001.
Nuclear Grade
2	5	1	80.0%	(51.6%, 100%)
3	70	32	54.9%	(43.9%, 68.8%)	0.264
Lymphovascular Invasion
Positive	18	10	44.4 %	(26.5%, 74.5%)
Negative	57	22	62.3 %	(50.1%, 77.3%)	0.073
Mutation Status
Mutant	15	2	86.2%	(70.0%, 100%)
Wild Type	62	31	51.7%	(40.3%, 66.7%)	0.031
Overall Survival Estimates
	N at risk	N Events	5-Year Estimate	95% Confidence Interval	P-Value
All		35	55.9 %	(44.7%,70.0 %)
Race
Black	18	10	30.8 %	(11.8%, 80.5%)
Spanish/Hispanic	8	2	75.0 %	(50.3%, 100%)
White	50	22	62.7 %	(50.2%, 78.2%)
Other	1	1	--	--	0.006
Age
≤ 50	36	15	60.7%	(44.6%, 82.7%)
> 50	41	20	53.4%	(40.1%, 71.2%)	0.279
Menopausal Status
Pre-menopausal	29	13	59.7%	(42.0%, 84.9%)
Post-menopausal	48	22	54.8%	(41.9%, 71.6%)	0.626
Histology
Ductal	64	29	57.0%	(44.8%, 72.6%)
Other	13	6	51.3%	(29.6%, 88.8%)	0.681
Pathological Stage
I and II	47	14	73.3%	(59.4%, 90.6%)
III	30	21	29.6%	(17.0%, 51.7%)	<0.001.
Nuclear Grade
2	5	2	80.0%	(51.6%, 100%)
3	70	33	52.8%	(41.0%, 68.1%)	0.675
Lymphovascular invasion
Positive	18	10	44.4 %	(26.5%, 74.5%)
Negative	57	24	59.5 %	(46.2%, 76.7%)	0.246
Mutation Status
Mutant	15	4	73.3%	(54.0%, 99.5%)
Wild Type	62	31	52.8%	(40.7%, 68.5%)	0.225